February 15, 2014 -- Luye Pharma will stage a $750 million IPO in Hong Kong after having delisted from the Singapore exchange two years ago; CR Double-Crane will distribute a Sagent Pharma orphan drug in China; the CFDA established a priority review process for innovative medical devices that renders a decision within either 60 or 40 working days; pharmaceutical foreign trade for China – in-bound and out-bound – rose 10% to $89.7 billion in 2013 with imports rising faster than exports; China researchers have created gold nanoshells that are designed to improve delivery of chemotherapies to tumors. More details….